Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03030170
Other study ID # 35RC15_9846
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date June 28, 2017
Est. completion date July 30, 2021

Study information

Verified date August 2023
Source Rennes University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Despite an improvement regarding morbidity and mortality since 30 years, especially in expert centers, pancreatic surgery remains currently associated to a significant postoperative morbidity reaching more than 60%. Regarding distal pancreatectomy (DP), the main complication following surgery is the occurrence of postoperative pancreatic fistula (PF) which may be able to lead an increased risk of bleeding, gastroparesis and finally a longer hospital stays. The main risk factors associated to the occurrence of pancreatic fistula are represented by the texture of the pancreatic parenchyma (soft pancreas) and the caliber of the main pancreatic duct (<3mm). Looking for new means of reducing the occurrence of pancreatic fistula is a priority in pancreatic surgery and a genuine public health issue. Currently, no formal recommendations concerning the optimal technical for closure of the distal stump in DP are available. In fact, manual closing by elective suturing or stapling of the main pancreatic duct give similar results. The use of a reinforcing stapling potentially represents a simple way to decrease the occurrence of pancreatic fistula and requires evaluation by a prospective randomized study.


Recruitment information / eligibility

Status Completed
Enrollment 207
Est. completion date July 30, 2021
Est. primary completion date December 14, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - All patients who undergo DP whether made by open or laparoscopic surgery - Patients 18 years of age or older, - Benefiting from a social security scheme, - Having given his free, informed and written consent. Exclusion Criteria: - History of pancreatic abdominal surgery - Severe co-morbidity type renal failure requiring hemodialysis, unbalanced diabetes, major respiratory insufficiency, heart failure = stage 3 NYHA; - Persons of full age who are subject to legal protection, persons deprived of liberty. - Pregnant or nursing women - Patients participating in or participating in another study

Study Design


Related Conditions & MeSH terms


Intervention

Device:
ENDO GIA X-tra Thick reload with Tri Staple Technology
Suture of the pancreas by normal stapling
ENDO GIA Articulating Reinforced Reload with Tri-Staple Technology
Suture of the pancreas by reinforced stapling

Locations

Country Name City State
France Service de chirurgie Hépato-pancréato-biliaire Clichy
France Service de chirurgie générale, digestive et de la transplantation hépatique Lyon
France AP-HM - Institut Paoli Calmettes_ service de chirurgie oncologique digestive Marseille
France Service de chirurgie digestive et endocrienne Nantes
France Institut Mutualiste Montsouris Paris 14
France Centre Hospitalier Universitaire Rennes Pontchaillou Rennes
France Unité d'hospitalisation Chirurgie hépatique, biliaire et pancréatique Villejuif

Sponsors (1)

Lead Sponsor Collaborator
Rennes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of postoperative pancreatic fistula defined by the criteria of the ISGPF up to 90 days
Secondary Gravity of the pancreatic fistula according to the 3 stages of ISGPF up to 90 days
Secondary Assessment of the occurrence of gastroparesis and its severity according to the criteria of ISGPS up to 90 days
Secondary Evaluation of the occurrence of postoperative haemorrhage up to 90 days
Secondary Length of hospital stay up to 90 days
Secondary Perioperative mortality and 90-day mortality up to 90 days
Secondary Overall morbidity classified and categorized according to the classification of Dindo and Clavien until 90 days
Secondary Rehospitalization rates until 90 days